SAN DIEGO and CALGARY, AB - Oncolytics Biotech Inc. (NASDAQ: NASDAQ:ONCY) (TSX: ONC), a biotechnology firm focused on immunotherapy for cancer, has received a notification from the Nasdaq regarding ...

Oncolytics (ONCY) announced that it received a delinquency notification letter from Nasdaq indicating that the company is not currently in ...

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for ...

Replimune's innovative cancer therapies, strong cash reserves, and FDA support position it to disrupt oncology markets. Click ...

that partners with biotech and small to mid-size pharma companies to accelerate the development of advanced and novel therapeutics, has released its latest report, Oncolytic Virus Therapy ...

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for ...

Venture Symbol: SRR All Issues: Yes Resumption (ET): 9:30 AM CIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company.

Oncolytics Biotech (NASDAQ:ONCY – Get Free Report)‘s stock had its “buy” rating reissued by HC Wainwright in a report released on Monday,Benzinga reports. They presently have a $5.00 target price on ...

The market is estimated to grow at a CAGR of 8.73% during the forecast period.... 7 fév 2025 Oncolytics Biotech® Announces Matt Coffey, Ph.D. Will Not Return to CEO Role Following Medical Leave of ...

H.C. Wainwright reaffirmed a Buy rating on Oncolytics Biotech (NASDAQ:ONCY) shares with a steady price target of $5.00. The stock, currently trading at $0.73 and near its 52-week low, shows potential ...

No sector is left unchanged by the power of AI and digital modeling, and Biotech is no exception. This is because biology is by far the most “messy” of hard sciences. Chemistry or physics can deal ...